Abstracts tagged "interferons and macrophages"

Abstract Number: 1111 • 2015 ACR/ARHP Annual Meeting
Relapse of Lupus after B-Cell Depletion Therapy Is Associated with Loss of Apoptotic Cell Clearance and Elevated Type I Interferon Responses in Lupus Prone BXD2
Hui-Chen Hsu^1,2, Zhaoqi Yan³, PingAr Yang², Qi Wu^1,2, Jennie Hamilton⁴, Jun Li⁵, Hao Li⁶, Bao Luo⁶, Laurie Harrington³ and John Mountz⁷, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Cell, Developmntl & Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Med/Rheumatology Div, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: B-cell depletion therapy (BCDT) is a promising therapy for autoimmune diseases but relapse can occur. In rheumatoid arthritis, patients who did not respond well…
Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting
Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity
Hao Li¹, Hui-Chen Hsu², Qi Wu³, Jun Li³, PingAr Yang³, Yang-Xin Fu⁴ and John D. Mountz⁵, ¹Dept. Med - Immunology/Rheumatology division, University of Alabama at Birmingham, Birmingham, AL, ²Birmingham VA Medical Center, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pathology, The University of Chicago, Chicago, IL, ⁵Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].